Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novartis ( (NVS) ) has provided an update.
On August 11, 2025, Novartis announced that its Phase III clinical trials for ianalumab, a novel treatment for Sjögren’s disease, successfully met their primary endpoints. The trials, NEPTUNUS-1 and NEPTUNUS-2, demonstrated statistically significant improvements in disease activity, positioning ianalumab as a potential first targeted treatment for this chronic autoimmune disease. The results are significant for Novartis as they plan to present the data at a medical congress and seek global health authority approvals, potentially enhancing their market position in autoimmune disease treatments.
The most recent analyst rating on (NVS) stock is a Hold with a $123.50 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Novartis’s overall stock score is driven by strong financial performance and a positive earnings call, which highlight robust growth and strategic initiatives. The valuation is reasonable, offering a good balance of growth and income. Technical analysis presents mixed signals, with some bearish momentum. The absence of significant corporate events leaves the focus on core financial and operational strengths.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis is an innovative medicines company focused on reimagining medicine to improve and extend people’s lives. The company operates in the pharmaceutical industry, providing a range of products and services aimed at treating various medical conditions.
Average Trading Volume: 1,635,872
Technical Sentiment Signal: Strong Buy
Current Market Cap: $221.9B
Find detailed analytics on NVS stock on TipRanks’ Stock Analysis page.